STIM Overview

Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.

Wall Street analysts forecast STIM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STIM is7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Neuronetics Inc revenue for the last quarter amounts to 34.45M USD, increased 7.75

Neuronetics Inc. EPS for the last quarter amounts to -0.16 USD, decreased -23.81

Neuronetics Inc (STIM) has 658 emplpoyees as of May 10 2026.

Today STIM has the market capitalization of 115.17M USD.